Document is current
Any future updates will be listed below
-
Authors
Asai, Yukako
Pan, Bifeng https://orcid.org/0000-0001-9746-3420
Nist-Lund, Carl
Galvin, Alice
Lukashkin, Andrei N. https://orcid.org/0000-0003-4577-8716
Lukashkina, Victoria A.
Chen, Tianwen
Zhou, Wu
Zhu, Hong
Russell, Ian J.
Holt, Jeffrey R.
Géléoc, Gwenaelle S. G.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (R01DC014930, R01DC012060, R01-DC013521)
U.S. Department of Health & Human Services | NIH | National Eye Institute (R21EY025550)
Medical Research Council (MR/N004299/1)
- License Information
-
More Information
Article History
Received: 27 March 2018
Accepted: 3 July 2018
First Online: 14 August 2018
Competing Interests
: G.S.G. and J.R.H. hold patents related to Tmc1 gene therapy. J.R.H. is a scientific advisor for Frequency Therapeutics and Applied Genetic Technologies Corporation.
